Adona Medical
Adona Medical is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Adona Medical.
Adona Medical is a company.
Key people at Adona Medical.
Key people at Adona Medical.
Adona Medical is a clinical-stage medical technology company developing a novel interatrial shunt with integrated bi-atrial pressure monitoring for patients with advanced heart failure.[1][2][3][5] The device features an adjustable flow channel that can be resized post-implantation using a proprietary induction catheter, alongside sensors capturing multiple daily pressure readings from both atria without patient interaction, enabling more personalized therapy.[1][2][3][5] It serves heart failure patients and physicians seeking individualized management beyond fixed-geometry shunts, addressing limitations in applicability and adoption of first-generation devices.[1][2] The company, a Shifamed portfolio firm based in Los Gatos, California, has raised $92.5M total funding, including a $33.5M Series C in July 2024 to advance product development and early clinical use, and completed enrollment in its first-in-human ATHENS-HF study in June 2025 with 100% procedural success in 10 patients.[1][3][4]
Adona Medical emerged as a Shifamed portfolio company, with Brian Fahey as Co-Founder and CEO, leveraging Shifamed's medical innovation hub to develop advanced heart failure solutions.[1][3] The idea stemmed from gaps in existing therapies, focusing on interatrial shunting with remote monitoring to enable post-implantation adjustments and proactive management.[1][2] Early traction included showcasing the platform at CSI Frankfurt 2023 and securing Series C funding led by Cormorant Asset Management in July 2024.[1][4] A pivotal moment came in June 2025 with completion of enrollment in the ATHENS-HF first-in-human study ahead of schedule, implanting the device in 10 patients and demonstrating strong early results.[3]
Adona rides the wave of personalized cardiovascular interventions amid rising heart failure prevalence, where first-generation devices face adoption barriers due to one-size-fits-all designs.[1][2] Timing aligns with advances in implantable sensors and remote monitoring, fueled by market demand for tailored therapies—heart failure affects millions, yet current options limit applicability.[1] Favorable forces include investor confidence (e.g., Shifamed backing, Cormorant-led funding) and clinical momentum, positioning Adona to influence medtech by setting standards for adjustable, sensor-enabled implants.[1][3] It contributes to the ecosystem by advancing Shifamed's portfolio in hemodynamic solutions, potentially disrupting fixed-shunt markets through superior patient outcomes and physician tools.[2][3]
Adona is poised to initiate evaluation of next-generation devices post-ATHENS-HF, expanding clinical programs and pursuing regulatory paths as an investigational device advances toward approval.[3] Trends like AI-augmented remote monitoring and precision medtech will shape its trajectory, amplifying data from bi-atrial sensors for predictive care. Its influence may grow by redefining heart failure standards, delivering the advanced solutions promised from inception and benefiting millions through Shifamed's innovation ecosystem.[1][3]
